-
Cyclooxygenase 2 (COX 2) inhibitors may not be as safe as previously thought. These agents have a considerable risk of adverse gastrointestinal events. The concurrent use of ulcer-healing drugs appears to decrease this risk.
-
The strong correlation between reduction of aura symptoms and migraine attacks stresses the potential role of aura-like events and possibly cortical spreading depression as a trigger for trigeminal vascular activation, and subsequently the development of migraine headaches.
-
A very small group of patients consume a significant portion of outpatient primary care physician time.
-
Infliximab, an antibody against tumor necrosis factor, is effective in ulcerative colitis.
-
A new drug has been approved for the treatment of children with below average height who are resistant to growth hormone. Mecasermin is a human insulin-like growth factor-1 (IGF-1) that is produced by recombinant DNA technology. This protein is marketed by Tercica, Incorporated as Increlex.
-
FDA Recommends Approval of Muraglitazar, But May Need To Reconsider; Which Antipsychotics Are More Dangerous?; Should CPOE Undergo Evaluation?; New Treatment for Tennis Elbow; FDA Actions
-
-
-
A program of resistive exercise and treadmill walking reduced the severity of restless legs syndrome symptoms.
-
People who have symptoms of allergic rhinitis report more sleep complaints, including daytime sleepiness, than do those without allergic rhinitis.
